Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Dogwood Therapeutics, Inc.

NASDAQ: DWTX · Life Sciences · 3 alerts · CIK 1818844

Share price
$1.06Close, Nov 16
Market cap
$40.5M
Shares outstanding
38.23MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Dogwood Therapeutics, Inc. filings on SEC EDGAR ↗

8:46 AM ET 8-K
Financial Results

Dogwood Therapeutics Financial Results

Dogwood Therapeutics reported third quarter 2026 financial results, highlighting the completion of its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain with top-line results expected in November 2026. The company also closed a $5 million private placement with Sealbond Limited to fund Phase 3 preparatory activities, extending its cash runway into the first quarter of 2027.

Term
3 months

“With results from the recently completed Phase 2b CINP study to be reported in November, we believe that if successful, Halneuron® could represent the first new therapeutic agent for millions of CINP patients in the US and tens of millions of CINP patients across the globe.”

Greg Duncan, Chief Executive Officer of Dogwood Therapeutics
8:45 AM ET 8-K
Capital Raise

Dogwood Therapeutics Capital Raise of $5M

Dogwood Therapeutics entered into a subscription agreement to sell 4,098,360 shares of common stock to its largest shareholder, Sealbond Limited (a subsidiary of CK Life Sciences), in a $5 million private placement. The proceeds will be used to fund Phase 3 preparatory activities for Halneuron® and extend the company's operational runway through March 2027.

Value
$5M
Counterparty
Sealbond Limited

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.